China yesterday said it has fined six mostly foreign baby formula producers, including New Zealand’s scandal-hit Fonterra, a total of US$108 million for price-fixing, as it seeks to cool public anger over the sector.
The penalties — also levied against firms from the US, France, the Netherlands and one Chinese company — came after a five-month inquiry by the National Development and Reform Commission (NDRC), China’s top economic planner.
They were a “record high” in Chinese anti-monopoly rulings, Xinhua news agency said.
They also come in the middle of the latest safety scare over formula, in which Fonterra has had to recall in several countries products tainted with a bacteria that can cause botulism, a potentially fatal disease.
It said yesterday that all the affected items had been removed from retailers’ shelves.
China is the world’s biggest market for formula and foreign-branded products are in high demand after repeated safety scandals involving domestic products — including one in 2008 when six children died and 300,000 were sickened.
Prices are high as a result, leading to frustrations among consumers.
The commission said in a statement it fined Mead Johnson and Abbott from the US; Dumex, a subsidiary of France’s Danone; a China arm of Royal FrieslandCampina of the Netherlands; Fonterra; and China’s Biostime (合生元).
The firms set minimum prices with distributors and punished dealers who did not comply, the commission said, and their actions reduced competition and “unjustifiably maintained high milk powder prices.”
“They undermined the fair market competition order and harmed consumers’ interests,” it added.
Mead Johnson said it had been fined 204 million yuan (US$33 million), adding it remains committed to the country that is “one of the company’s most important markets.”
Biostime, based in Guangzhou, said in a filing to the Hong Kong stock exchange that it would pay a fine of 163 million yuan “in a timely manner.”
The value is about 6 percent of the company’s sales revenue in the previous year — the highest rate among all firms punished — because its violations were “grave” and it “failed to rectify its wrongdoings in an active way,” the commission said.
Fonterra said it was fined 4.5 million yuan and accepted the decision.
Its chief executive, Theo Spierings, said all tainted products, which were distributed in countries ranging from New Zealand to Saudi Arabia, had been removed.
“All the stocks have been contained, everything is out of the market,” he told reporters in Auckland. “It’s in warehouses and there is little or no more risk for consumers.”
The commission said Dumex was fined 172 million yuan, Abbott 77 million yuan and FrieslandCampina 48 million yuan.
Chinese authorities are also investigating 60 foreign and domestic pharmaceutical firms over how they set prices. In a high-profile case last month they arrested four executives from British drug firm GlaxoSmithKline for alleged bribery and other offenses.
Shaun Rein, the managing director of China Market Research Group in Shanghai, said authorities were right to bring down prices of vital goods such as baby formula and medicine.
“Prices on both have been spiraling out of control over the last 10 years,” he said.
Beijing tended to target foreign firms because “it scares everybody else into line,” but avoided antagonizing powerful domestic players. However, Rein said firms may have inflated baby formula prices partly as a marketing ploy to signal to consumers that they represented the quality and safety they sought.
The commission launched the dairy products investigation in March, mostly targeting overseas firms, and several of them announced price cuts last month.
Three companies — Wyeth, which is owned by Swiss giant Nestle, Japan’s Meiji and Chinese firm Beingmate (貝因美) — had been exempted from punishment, the commission said.
They provided important evidence and carried out active self-rectification, it added.
NEW MARKET: The partnership opens up India to the Dutch company, which already has a strong hold in the semiconductor market of South Korea, Taiwan and China ASML Holding NV entered into a partnership agreement with Tata Electronics Pvt Ltd aimed at ramping up India’s goal to develop domestic chip-manufacturing capabilities. The Dutch company’s technology would help power Tata Electronics’ planned 300 millimeter (mm) semiconductor foundry in Gujarat, according to a joint statement from the two companies on Saturday. The signing of a memorandum of understanding coincides with a visit by Indian Prime Minister Narendra Modi to the Netherlands, which is looking to deepen bilateral relations with New Delhi. ASML, whose top customers include Taiwan Semiconductor Manufacturing Co (台積電) and Samsung Electronics Co, makes lithography machines that can print
ROUGH RECORDS: Bonds in Japan, as well is in New Zealand, Australia and the US, are seeing the effects of a nervy market as stock exchanges across Asia edge down A deepening slump in Japanese government bonds added fuel to the selloff in global debt markets as rising oil prices stoked inflation fears and pushed yields to multi-decade highs. Japan’s 30-year yield yesterday surged as much as 20 basis points to the highest level since the tenor’s debut in 1999, before paring some of the move. Shorter-maturity Japanese debt was also under pressure, underscored by weak demand at a sale of five-year notes that offered a record-high coupon of 2 percent. Concerns over inflation and government spending rippling through markets including the US, Australia and New Zealand are being amplified in Japan,
Tokyo Electron's Taiwan unit today said in a written response that it respects the judicial process, takes the court ruling seriously and would not appeal in the Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) trade secrets case. Last month, a court fined the Taiwan unit of Japan's Tokyo Electron NT$150 million (US$4.74 million) in a case involving trade secrets related to TSMC's sensitive chip technology.
Wall Street is licking its chops over an unprecedented slate of massive initial public offerings (IPOs) set to arrive in the coming months, beginning with Elon Musk’s Space Exploration Technologies Corp (SpaceX) next month. That is expected to be followed by artificial intelligence (AI) rivals OpenAI and Anthropic PBC. The trio of mega listings, each eyeing valuations around US$1 trillion or more, constitutes a heady period of elevated risk and reward. SpaceX is targeting an IPO that would raise up to US$80 billion — about double the funds generated from all IPOs last year. OpenAI and Anthropic are eyeing IPOs raising US$60 billion. “We’re